Raloxifene therapy for 3 years reduces the risk of incident vertebral fractures in postmenopausal women
PD Delmas, H K Genant, Jean‐Yves Reginster(King Saud University), Steven A. Harris(Pacific University Oregon), H.A.P. Pols, B. Mitlak(Eli Lilly (United States)), Robert R. Recker(Creighton University), RK Knickerbocker, KE Ensrud, Richard Eastell(University of Sheffield), N. H. Bjarnason(Center for Clinical & Basic Research), C. Gennari, Adachi, D Black
ORBi (University of Liège)
January 1, 1999
Cited by 4
Related Papers
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
|Osteoporosis International|2012|2.9k
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
|Osteoporosis International|2018|1.8k
A Mutation in the LDL Receptor–Related Protein 5 Gene Results in the Autosomal Dominant High–Bone-Mass Trait
|The American Journal of Human Genetics|2002|1.3k
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
|Journal of Bone and Mineral Research|2004|1.2k
Low Body Mass Index Is an Important Risk Factor for Low Bone Mass and Increased Bone Loss in Early Postmenopausal Women
|Journal of Bone and Mineral Research|1999|455